Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 38Lung Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Neoplasms 16Uterine Cervical Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Carcinoma, Hepatocellular 10Sarcoma 9Rectal Neoplasms 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Neoplasm Metastasis 8Melanoma 8Lymphoma 8Glioblastoma 8Colorectal Neoplasms 8Brain Neoplasms 8Thyroid Neoplasms 7Stomach Neoplasms 7Solid Tumor 7Pancreatic Neoplasms 7Oropharyngeal Neoplasms 7Multiple Myeloma 7Head and Neck Neoplasms 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms, Male 6

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 43fludarabine phosphate 42Mycophenolic Acid 30Whole-Body Irradiation 27Cyclosporine 27Busulfan 26Tacrolimus 23Antilymphocyte Serum 23Methotrexate 20Etoposide 20romidepsin 19Filgrastim 19Melphalan 16Radiotherapy 15Flow Cytometry 15Vorinostat 13Methylprednisolone 13Brentuximab Vedotin 13Lenalidomide 12Bexarotene 12mogamulizumab 11Psychiatric Rehabilitation 11Bortezomib 11Therapeutics 10Rituximab 10Gemcitabine 10fludarabine 9Polymerase Chain Reaction 9Biopsy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Fluorodeoxyglucose F18 × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡